期刊文献+

丙型肝炎规范化与个体化治疗 被引量:1

下载PDF
导出
摘要 丙型肝炎(HC)是由丙型肝炎病毒(HCV)引起的、以肝脏受累为主的全身疾病。HCV除可以侵犯肝脏外,肾脏、骨髓、甲状腺等其他器官均可受累,而表现为全身性疾病。人感染HCV后,50%-80%会发展为慢性丙型肝炎(CHC),自发清除病毒的比例很低。对于CHC患者来说,如果没有进行及时有效的抗病毒治疗,绝大多数将逐渐发展为肝硬化、肝功能失代偿,甚至肝细胞癌。
作者 丁洋 窦晓光
出处 《临床内科杂志》 CAS 2015年第8期515-517,共3页 Journal of Clinical Internal Medicine
基金 国家“十二五”科技重大专项项目(2012ZX10002003) 2014年辽宁省临床能力建设项目(LNCCC-A02-2014)
  • 相关文献

参考文献23

  • 1张长江,朱研,王小红.慢性丙型肝炎病毒感染的肝外表现[J].中华传染病杂志,2011,39(2):124-128. 被引量:4
  • 2Mohd Hanafiah K,Groeger J,Flaxman AD,et al.Global epidemiology of hepatitis C virus infection:new estimates of age-specific antibody to HCV seroprevalence[J].Hepatology,2013,57(4):1333-1342.
  • 3Morgan RL,Baack B,Smith BD,et al.Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma:a meta-anal- y sis of observational studies[J].Ann Intern Med,2013,158(5 Pt I):329-337.
  • 4Pizarro C,Venegas M,Hola K,et al.Results of treatment with peginter- feron plus ribavirin in patients with chronic hepatitis[J].Rev Med Chil,2011,139(6):704-709.
  • 5Toyoda H,Kumada T.Incidence of hepatocellular carcinoma and re- sponse to interferon therapy in HCV-infected patients:effect of factors associated with the therapeutic response and incidence of HCC[J].Liver Int,2012,32(16):1029-1031.
  • 6Swain MG,Lai MY,Shiffman ML,et al.A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin[J].Gastroenterology,2010,139(5):1593-1601.
  • 7魏来.丙型肝炎抗病毒治疗的历史和发展[J].临床内科杂志,2013,30(11):727-729. 被引量:8
  • 8Fried MW,Buti M,Dore GJ,et al.Once-daily simeprevir(TMC435) with pegylated interferon and ribavirin in treatment naive genotype I hepatitis C:the randomized PILLAR study[J].Hepatology,2013,58(6):1918-1929.
  • 9Lawitz E,Lalezari JP,Hassanein T,et al.Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic,treatment-naive pa- tients with genotypes 1,2,and 3 hepatitis C infection:a randomised,double-blind,phase 2 trial[J].Lancet Infect Dis,2013,13(5):401-408.
  • 10European Association for the Study of the Liver.EASL Clinical Practice Guidelines:Management of hepatitis C virus infection[J].J Hepatol,2014,60(2):392-420.

二级参考文献14

  • 1Manns MP,McHutchison JG,Gordon SC,et al.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomised trial.Lancet,2001,358:958-965.
  • 2Fried MW,Shiffman ML,Reddy KR,et al.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.N EnglJ Med,2002,347:975-982.
  • 3Lok AS,Gardiner DF,Lawitz E,et al.Preliminary study of two antiviral agents for hepatitis C genotype 1.N EnglJ Med,2012,366:216-224.
  • 4Kowdley KV,Lawitz E,Poordad F,et al.Safety and efficacy of interferon-free regimens of ABT-450/r,ABT-267,ABT-333 +/-ribavirin in patients with chronic HCV GT1 infection:results from the AVIATOR study.Journal of Hepatology,2013,58:S2.
  • 5Gane E J,Stedman CA,Hyland RH,et al.All-oral SOFOSBUVIR-based 12-week regimens for the treatment of chronic HCV infection:the ELECTRON study.Journal of Hepatology,2013,58:s6.
  • 6Gane E,Lawitz E,Rodriguez-Torres M,et al.Phase 3 randomized controlled trial of all-oral treatment with Sofosbuvir + ribavirin for 12 weeks compared to 24 weeks of Peg + ribavirin in treatment-naive GT2/3HCV-infected patients (FISSION).Journal of Hepatology,2013,58:s3.
  • 7Nelson DR,Feld J,Kowdley KV,et al.All oral therapy with Sofosbuvir + ribavirin for 12 or 16 weeks in treatment experienced GT2/3 HCV-infected patients:results of the Phase 3 FUSION trial.Journal of Hepatology,2013,58:S3.
  • 8Sulkowski MS,Gardiner DF,Rodriguez-Torres M,et al.Sustained virologic response with daclatasvir plus sofosbuvir ± ribavirin (RBV) in chronic HCV genotype(GT) 1-infected patients who previously failed telaprevir(TVR) or Boceprevir (BOC).Journal of Hepatology,2013,58:s570.
  • 9Chayama K,Suzuki Y,Ikeda K,et al.All-oral Combination of Daclatasvir Plus Asunaprevir in Interferon Ineligible Naive/Intolerant and Nonresponder Japanese Patients Chronically Infected with HCV Genotype 1b:Results from a Phase 3 Trial.Hepatology,2013,58:s313A.
  • 10Lawitz E,Hezode C,Varunok P,et al.Interferon-and Ribavirin-free Regimen of ABT-450/r + ABT-267 in HCV Genotype 1 b-infected Treatment-na? ve Patients and Prior Null Responders.Hepatology,2013,58:s244A.

共引文献10

同被引文献14

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部